Progenics Pharma (PGNX) Reports Q4 Loss of $0.10/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. CVS
10. SPY

Go back to Progenics Pharma (PGNX) Reports Q4 Loss of $0.10/Share

Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2016 Financial Results and Business Update

March 9, 2017 7:32 AM EST

Registrational Phase 2B Trial Topline Results for Ultra-Orphan Radiotherapeutic Candidate AZEDRA® Expected First Quarter 2017Independent DMC Recommended Continuation of Enrollment of Phase 3 Trial for Imaging Agent 1404Initiated Phase 2/3 Trial of PyL Imaging AgentIn February 2017, Initiated Phase 1 Trial of PSMA Targeted Therapeutic Candidate 1095Monetized Portion of RELISTOR Royalty Stream through $50 Million TransactionFourth Quarter 2016 RELISTOR (SC and Oral) Net Sales of $16 Million

NEW YORK, March 09, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced financial results and provided a business update for the fourth... More